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Low-Density Lipoprotein
Cholesterol?The ACCF/AHA welcomes letters to inform its ongoing work and
encourages such correspondence about its guidelines. Because the
ACCF/AHA guideline development process is rigorous and in-
volves several layers of review by the writing committee, external
peer reviewers, and participating organizations in the document, it
cannot respond to each issue raised after a guideline has been
published. The information, however, is forwarded to the writing
committee chair and oversight task force for review. If any issue is
deemed by the ACCF/AHA to affect patient safety, it will be
considered immediately. Otherwise, the information will be
considered during the next update or revision of the guideline.The American College of Cardiology
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